Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

224 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

VX-950HPC3006 NCT01571583 Enrollment Information - VX-950HPC3006 Enrollment Information

- 15.03.16 - 1 Formulário, 1 Grupo de itens, 2 Elementos de dados, 1 Idioma
Grupo de itens: Enrollment Information
This is an open-label (all people know the identity of the intervention), multicenter study in genotype 1 chronic HCV infected liver transplant patients who will be treated for 12 weeks with telaprevir 750 mg every 8 hours given in combination with Peg-IFN-alfa-2a and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone. The total treatment duration will be 48 weeks. Safety will be evaluated throughout the study and will include evaluations of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination. NCT01571583

VX-950HPC3006 NCT01571583 Laboratory Blood Urine Pregnancy - VX-950HPC3006 Laboratory - Blood, urine, pregnancy

- 14.03.16 - 1 Formulário, 1 Grupo de itens, 7 Elementos de dados, 1 Idioma
Grupo de itens: Laboratory blood urine pregnancy
This is an open-label (all people know the identity of the intervention), multicenter study in genotype 1 chronic HCV infected liver transplant patients who will be treated for 12 weeks with telaprevir 750 mg every 8 hours given in combination with Peg-IFN-alfa-2a and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone. The total treatment duration will be 48 weeks. Safety will be evaluated throughout the study and will include evaluations of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination. NCT01571583

VX-950HPC3006 NCT01571583 Screening Physical Examination - VX-950HPC3006 Screening Physical Examination

- 14.03.16 - 1 Formulário, 15 Grupos de itens, 59 Elementos de dados, 1 Idioma
Grupos de itens: Date of examination, General Appearance, Skin and mucous membranes, Eyes, Funduscopic exam, Ears, nose, throat, Cardiovascular system, Respiratory system, Gastrointestinal system, Genito-urinary system, neurological system, musculo-skeletal system, lymph nodes, anorectal, other abnormality
This is an open-label (all people know the identity of the intervention), multicenter study in genotype 1 chronic HCV infected liver transplant patients who will be treated for 12 weeks with telaprevir 750 mg every 8 hours given in combination with Peg-IFN-alfa-2a and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone. The total treatment duration will be 48 weeks. Safety will be evaluated throughout the study and will include evaluations of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination. NCT01571583

VX-950HPC3006 NCT01571583 Vital Signs / Anthropometric Measurements - VX-950HPC3006 Vital Sign / Anthropometric Measurements

- 10.03.16 - 1 Formulário, 1 Grupo de itens, 7 Elementos de dados, 1 Idioma
Grupo de itens: Vital signs and anthropometric measurements
This is an open-label (all people know the identity of the intervention), multicenter study in genotype 1 chronic HCV infected liver transplant patients who will be treated for 12 weeks with telaprevir 750 mg every 8 hours given in combination with Peg-IFN-alfa-2a and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone. The total treatment duration will be 48 weeks. Safety will be evaluated throughout the study and will include evaluations of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination. NCT01571583

VX-950HPC3006 NCT01571583 Prior treatment history - VX-950HPC3006 Prior treatment history

- 10.03.16 - 1 Formulário, 3 Grupos de itens, 17 Elementos de dados, 1 Idioma
Grupos de itens: Prior treatment outcome, Prior HCV therapy, Prior HCV RNA results
This is an open-label (all people know the identity of the intervention), multicenter study in genotype 1 chronic HCV infected liver transplant patients who will be treated for 12 weeks with telaprevir 750 mg every 8 hours given in combination with Peg-IFN-alfa-2a and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone. The total treatment duration will be 48 weeks. Safety will be evaluated throughout the study and will include evaluations of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination. NCT01571583

VX-950HPC3006 NCT01571583 Liver Disease History - VX-950HPC3006 Liver Disease History

- 10.03.16 - 1 Formulário, 2 Grupos de itens, 9 Elementos de dados, 1 Idioma
Grupos de itens: Liver Disease History, Liver Graft Biopsy Result
This is an open-label (all people know the identity of the intervention), multicenter study in genotype 1 chronic HCV infected liver transplant patients who will be treated for 12 weeks with telaprevir 750 mg every 8 hours given in combination with Peg-IFN-alfa-2a and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone. The total treatment duration will be 48 weeks. Safety will be evaluated throughout the study and will include evaluations of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination. NCT01571583

VX-950HPC3006 NCT01571583 Medical/Surgical History and Concomitant Disease - VX-950HPC3006 Medical/Surgical History and Concomitant Disease

- 10.03.16 - 1 Formulário, 16 Grupos de itens, 58 Elementos de dados, 1 Idioma
Grupos de itens: Medical/Surgical History and Concomitant Disease, Allergic/Immunologic Diseases, Dermatological diseases, Pruritic skin condition, Respiratory diseases, Cardiovascular disease, Endocrine disease, Gastrointestinal disease, Genito-urinary disease, Hematological disease, Muscuko-skeletal disease, Neurological Disease, Psychiatric Disease, Ophthalmological disorders, ENT disorder, Other comorbidity
This is an open-label (all people know the identity of the intervention), multicenter study in genotype 1 chronic HCV infected liver transplant patients who will be treated for 12 weeks with telaprevir 750 mg every 8 hours given in combination with Peg-IFN-alfa-2a and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone. The total treatment duration will be 48 weeks. Safety will be evaluated throughout the study and will include evaluations of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination. NCT01571583

VX-950HPC3006 NCT01571583 Family History of Diseases - VX-950HPC3006 Family History of Diseases

- 10.03.16 - 1 Formulário, 1 Grupo de itens, 12 Elementos de dados, 1 Idioma
Grupo de itens: Family History of Diseases
This is an open-label (all people know the identity of the intervention), multicenter study in genotype 1 chronic HCV infected liver transplant patients who will be treated for 12 weeks with telaprevir 750 mg every 8 hours given in combination with Peg-IFN-alfa-2a and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone. The total treatment duration will be 48 weeks. Safety will be evaluated throughout the study and will include evaluations of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination. NCT01571583

VX-950HPC3006 NCT01571583 History Clinical Trials - VX-950HPC3006 History Clinical Trails

- 10.03.16 - 1 Formulário, 7 Grupos de itens, 14 Elementos de dados, 1 Idioma
Grupos de itens: TMC114, TMC125, TMC278, TMC207, VX950, TMC120, TMC 435
This is an open-label (all people know the identity of the intervention), multicenter study in genotype 1 chronic HCV infected liver transplant patients who will be treated for 12 weeks with telaprevir 750 mg every 8 hours given in combination with Peg-IFN-alfa-2a and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone. The total treatment duration will be 48 weeks. Safety will be evaluated throughout the study and will include evaluations of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination. NCT01571583

VX-950HPC3006 NCT01571583 Demographic Date and Informed Consent Recording - VX-950HPC3006 Demographic Date and Informed Consent Recording

- 10.03.16 - 1 Formulário, 3 Grupos de itens, 26 Elementos de dados, 1 Idioma
Grupos de itens: Demography, Clinical Trial History, Subject Identification
This is an open-label (all people know the identity of the intervention), multicenter study in genotype 1 chronic HCV infected liver transplant patients who will be treated for 12 weeks with telaprevir 750 mg every 8 hours given in combination with Peg-IFN-alfa-2a and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone. The total treatment duration will be 48 weeks. Safety will be evaluated throughout the study and will include evaluations of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination. NCT01571583

VX-950HPC3006 NCT01571583 InForm Screening - VX-950HPC3006 InForm Screening

- 09.03.16 - 1 Formulário, 1 Grupo de itens, 3 Elementos de dados, 1 Idioma
Grupo de itens: Subject Basic Information
This is an open-label (all people know the identity of the intervention), multicenter study in genotype 1 chronic HCV infected liver transplant patients who will be treated for 12 weeks with telaprevir 750 mg every 8 hours given in combination with Peg-IFN-alfa-2a and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone. The total treatment duration will be 48 weeks. Safety will be evaluated throughout the study and will include evaluations of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination. NCT01571583

VX-950HPC3006 NCT01571583 InForm Enrollment - VX-950HPC3006 InForm Enrollment

- 09.03.16 - 1 Formulário, 1 Grupo de itens, 2 Elementos de dados, 1 Idioma
Grupo de itens: Study subject data
This is an open-label (all people know the identity of the intervention), multicenter study in genotype 1 chronic HCV infected liver transplant patients who will be treated for 12 weeks with telaprevir 750 mg every 8 hours given in combination with Peg-IFN-alfa-2a and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone. The total treatment duration will be 48 weeks. Safety will be evaluated throughout the study and will include evaluations of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination. NCT01571583

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial